Prograf generics begin to bite at Astellas
This article was originally published in Scrip
Astellas's total net sales edged up by 2% to ¥772.8 billion ($8.52 billion) in the nine months to December 31st, with growth being constrained by the strong yen and increasing generic competition for top product Prograf (tacrolimus).
You may also be interested in...
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.